Alternative splicing of RAGE: Roles in biology and disease

Anastasia Z. Kalea; Ann Marie Schmidt; Barry I. Hudson

doi:10.2741/3884

Alternative splicing of RAGE: Roles in biology and disease

Anastasia Z. Kalea, Ann Marie Schmidt, Barry I. Hudson

Medicine

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Abstract

The Receptor for Advanced Glycation End-products (RAGE) is a complex, multi-ligand signaling system implicated in the pathogenesis of diabetes, cardiovascular disease and various cancers. RAGE undergoes extensive alternative splicing to produce a variety of transcripts with diverse functions, including soluble antagonists and variants with altered ligand binding domains. Studies focused on the major soluble variant (RAGEv1/esRAGE) have revealed this to function by binding RAGE-ligands and preventing activation of RAGE signaling in vascular and tumor cells. Furthermore, measurement of this variant in human serum has revealed that RAGEv1/esRAGE levels may represent a novel biomarker for RAGE-ligand related pathogenic states. Understanding the full plethora of RAGE alternative splicing and its regulation is central to elucidating the role of RAGE in biology and disease.

Original language	English (US)
Pages (from-to)	2756-2770
Number of pages	15
Journal	Frontiers in Bioscience
Volume	16
Issue number	7
DOIs	https://doi.org/10.2741/3884
State	Published - Jun 1 2011

Keywords

Advanced Glycation End-products
Alternative splicing
mRNA
Receptors
Review

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Immunology and Microbiology(all)
Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2741/3884

Cite this

@article{f1bf189e00224c25a7ba258bedd2df7e,

title = "Alternative splicing of RAGE: Roles in biology and disease",

abstract = "The Receptor for Advanced Glycation End-products (RAGE) is a complex, multi-ligand signaling system implicated in the pathogenesis of diabetes, cardiovascular disease and various cancers. RAGE undergoes extensive alternative splicing to produce a variety of transcripts with diverse functions, including soluble antagonists and variants with altered ligand binding domains. Studies focused on the major soluble variant (RAGEv1/esRAGE) have revealed this to function by binding RAGE-ligands and preventing activation of RAGE signaling in vascular and tumor cells. Furthermore, measurement of this variant in human serum has revealed that RAGEv1/esRAGE levels may represent a novel biomarker for RAGE-ligand related pathogenic states. Understanding the full plethora of RAGE alternative splicing and its regulation is central to elucidating the role of RAGE in biology and disease.",

keywords = "Advanced Glycation End-products, Alternative splicing, mRNA, Receptors, Review",

author = "Kalea, {Anastasia Z.} and Schmidt, {Ann Marie} and Hudson, {Barry I.}",

year = "2011",

month = jun,

day = "1",

doi = "10.2741/3884",

language = "English (US)",

volume = "16",

pages = "2756--2770",

journal = "Frontiers in Bioscience - Landmark",

issn = "1093-9946",

publisher = "Frontiers in Bioscience",

number = "7",

}

TY - JOUR

T1 - Alternative splicing of RAGE

T2 - Roles in biology and disease

AU - Kalea, Anastasia Z.

AU - Schmidt, Ann Marie

AU - Hudson, Barry I.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - The Receptor for Advanced Glycation End-products (RAGE) is a complex, multi-ligand signaling system implicated in the pathogenesis of diabetes, cardiovascular disease and various cancers. RAGE undergoes extensive alternative splicing to produce a variety of transcripts with diverse functions, including soluble antagonists and variants with altered ligand binding domains. Studies focused on the major soluble variant (RAGEv1/esRAGE) have revealed this to function by binding RAGE-ligands and preventing activation of RAGE signaling in vascular and tumor cells. Furthermore, measurement of this variant in human serum has revealed that RAGEv1/esRAGE levels may represent a novel biomarker for RAGE-ligand related pathogenic states. Understanding the full plethora of RAGE alternative splicing and its regulation is central to elucidating the role of RAGE in biology and disease.

AB - The Receptor for Advanced Glycation End-products (RAGE) is a complex, multi-ligand signaling system implicated in the pathogenesis of diabetes, cardiovascular disease and various cancers. RAGE undergoes extensive alternative splicing to produce a variety of transcripts with diverse functions, including soluble antagonists and variants with altered ligand binding domains. Studies focused on the major soluble variant (RAGEv1/esRAGE) have revealed this to function by binding RAGE-ligands and preventing activation of RAGE signaling in vascular and tumor cells. Furthermore, measurement of this variant in human serum has revealed that RAGEv1/esRAGE levels may represent a novel biomarker for RAGE-ligand related pathogenic states. Understanding the full plethora of RAGE alternative splicing and its regulation is central to elucidating the role of RAGE in biology and disease.

KW - Advanced Glycation End-products

KW - Alternative splicing

KW - mRNA

KW - Receptors

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=79959567198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959567198&partnerID=8YFLogxK

U2 - 10.2741/3884

DO - 10.2741/3884

M3 - Article

C2 - 21622207

AN - SCOPUS:79959567198

VL - 16

SP - 2756

EP - 2770

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 7

ER -

Alternative splicing of RAGE: Roles in biology and disease

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this